BriaCell Therapeutics (TSX:BCT) EBIT : C$-45.38 Mil (TTM As of Jul. 2024)

BriaCell Therapeutics EBIT Chart

BriaCell Therapeutics Annual Data
	Trend	Jul15	Jul16	Jul17	Jul18	Jul19	Jul20	Jul21	Jul22	Jul23	Jul24
EBIT		Get a 7-Day Free Trial					-5.39	-17.21	-34.72	-30.75	-45.71

BriaCell Therapeutics Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
EBIT	Get a 7-Day Free Trial															-10.18	-11.66	-13.19	-12.62	-7.91

Competitive Comparison of BriaCell Therapeutics's EBIT

For the Biotechnology subindustry, BriaCell Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BriaCell Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's EV-to-EBIT falls into.

BriaCell Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-45.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics  (TSX:BCT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BriaCell Therapeutics's annualized ROC % for the quarter that ended in Jul. 2024 is calculated as:

where

Note: The Operating Income data used here is four times the quarterly (Jul. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

BriaCell Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2024 is calculated as:

where Working Capital is:

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jul. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BriaCell Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics Business Description